8-K: Tenon Medical Faces Nasdaq Listing Compliance Issues Following Director Resignation

Tenon Medical has received a notice from Nasdaq for not meeting the minimum requirements for independent directors on its board and key committees after a director's resignation.

Summary

• Tenon Medical received a notice from Nasdaq on January 4, 2024, stating they are not in compliance with listing rule 5605.
• The non-compliance is due to the resignation of Frank Fischer from the Board of Directors, Audit Committee, and Compensation Committee, effective November 30, 2023.
• Nasdaq Listing Rule 5605 requires a majority of the board to be independent, the Audit Committee to have at least three independent directors, and the Compensation Committee to have at least two independent directors.
• Currently, Tenon Medical has six directors, with only three qualifying as independent.
• The Audit Committee has only two independent directors, and the Compensation Committee has only one.
• Tenon Medical has until the earlier of their next annual shareholders meeting or November 30, 2024, to regain compliance.
• If the next annual shareholders meeting is before May 28, 2024, compliance must be demonstrated by May 28, 2024.
• The company intends to appoint one or more independent directors to rectify the situation.

Sentiment

Score: 3

Explanation: The document highlights a significant governance issue and potential risk of delisting, which is negative for investors. However, the company has a cure period and intends to rectify the situation.

Positives

• The notice does not immediately affect the listing or trading of the company's stock.
• Tenon Medical has a cure period to regain compliance with Nasdaq listing rules.
• The company intends to appoint new independent directors to address the issue.

Negatives

• Tenon Medical is currently not in compliance with Nasdaq listing rules.
• The resignation of a key director has caused a significant governance issue.
• The company needs to act quickly to appoint new independent directors.

Risks

• Failure to regain compliance with Nasdaq listing rules could lead to delisting.
• The company's reputation could be negatively impacted by the non-compliance notice.
• The need to quickly appoint new directors could lead to less than ideal candidates being selected.

Future Outlook

The company intends to elect one or more independent directors to serve on the Board, Audit Committee, and Compensation Committee to regain compliance with Nasdaq listing rules.

Management Comments

• The company intends to elect one or more independent directors to serve as a member of the Board, the Audit Committee and the Compensation Committee during this cure period.

Industry Context

This type of non-compliance is not uncommon, especially after a key director's resignation. Companies listed on exchanges like Nasdaq must maintain specific governance standards, and failure to do so can lead to delisting if not rectified within the given timeframe.

Comparison to Industry Standards

• Nasdaq listing rules are designed to ensure a minimum level of corporate governance and independence.
• Many companies on the Nasdaq have similar requirements for independent directors on their boards and committees.
• Companies like InMode Ltd. and Globus Medical Inc. also have similar requirements for independent directors on their boards and committees.
• Failure to meet these standards can lead to similar non-compliance notices and potential delisting if not addressed.

Management Changes

Stakeholder Impact

• Shareholders may be concerned about the potential for delisting.
• Employees may be concerned about the company's stability.
• Creditors may be concerned about the company's ability to meet its obligations.

Next Steps

• Tenon Medical needs to appoint one or more independent directors to the Board, Audit Committee, and Compensation Committee.
• The company must demonstrate compliance with Nasdaq listing rules by the earlier of the next annual shareholders meeting or November 30, 2024, or May 28, 2024, if the meeting is before that date.

Key Dates

Keywords

Nasdaq, compliance, independent directors, board of directors, audit committee, compensation committee, listing rules, corporate governance, delisting